Is EP Biocomposites overvalued or undervalued?

As of 17 November 2025, the valuation grade for EP Biocomposites has moved from expensive to fair. The company is currently fairly valued based on its financial metrics. Key ratios include a PE ratio of 15.35, an EV to EBIT of 11.15, and an ROCE of 12.38%.
In comparison to peers, EP Biocomposites has a similar valuation to Sagility, which is also rated fair with a PE of 29.82, but significantly lower than Altius Telecom, which is rated very attractive with a PE of 51.5. Notably, EP Biocomposites has seen a substantial decline in stock performance, with a year-to-date return of -45.03%, contrasting sharply with the Sensex's gain of 8.72% during the same period.